BUY Biocon Ltd — Swati Hotkar, Nirmal Bang Securities
bySwati Hotkar, Nirmal Bang SecuritiesHorizon: NA (inferred Swing (≤2wk))4 Aug 2026via NDTV Profit
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.
5 advisors have active short-term BUY calls on this stock, with 2 issued in the last 14 days
Advisor consensus · adjacent horizon·17 Aug · today
Biocon Shares Surge Nearly 3% After Q1 Profit Jumps 350%
NewsNdtv-Profit·6 Aug · 2w ago
Biocon Q1 Results: Profit Spikes 350%, Revenue Exceeds Rs 4,300 Crore
NewsNdtv-Profit·5 Aug · 2w ago
Biocon Q1 Results: Net profit jumps over four-fold as biopharma business drives growth
NewsCnbc-Tv18·5 Aug · 2w ago
Biocon Q1FY27 Total Income at Rs 4,391 Cr (up 9%), EBITDA at Rs 902 Cr, Net Profit at Rs 141 Cr, with Biopharma Revenue up 17%.
NSE · Press Release·5 Aug · 2w ago
Q1 Results Today Highlights: Godrej Agrovet posts mixed Q1; Whirlpool PAT falls 34%, Berger Paints, Biocon, Shilpa Medicare, Aster DM, Navin Fluorine report profit growth
NewsHbl·5 Aug · 2w ago
From profit surges to margin worries: The big takeaways from Wednesday's earnings
NewsCnbc-Tv18·5 Aug · 2w ago
Biocon Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
NSE · Outcome of Board Meeting·5 Aug · 2w ago
Market Pulse: Key triggers to watch before the Aug 5 trading session
NewsCnbc-Tv18·4 Aug · 2w ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.